Advanced Search
Contact | Corporate | Help

Expanded Cohort for MCRC Using Bevacizumab + Everolimus

Sponsors:
  • Duke University
  • Novartis Pharmaceuticals
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
BEV/EV
  • Colorectal Adenocarcinoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: bevacizumab + everolimus
Enrollment:
50

Additional information about NCT00597506.


SourceSolution © 2008-2012